Keytruda® (pembrolizumab) – Expanded indication
November 16, 2023 - Merck announced the FDA approval of Keytruda (pembrolizumab), in combination with fluoropyrimidine-and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Top